TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05513170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed sinus lift using osteotomes
Description: Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
Study: NCT04926701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose
Description: Single doses of inhaled placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 multiple twice daily doses
Description: Ascending doses of inhaled ETD001 administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 multiple twice daily doses
Description: Ascending doses of inhaled ETD001 administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple twice daily doses
Description: Doses of inhaled placebo administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple twice daily doses
Description: Doses of inhaled placebo administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 multiple once daily doses
Description: Doses of inhaled ETD001 administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple once daily doses
Description: Doses of inhaled placebo administered once daily
Study: NCT06070545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Supine Position
Description: Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
Study: NCT06273709

Intervention type: DEVICE
Intervention: Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner
Description: (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).

Intervention type: DEVICE
Intervention: Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner
Description: (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
Study: NCT05462717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6291
Description: Oral tablet once or twice a day
Study: NCT06406010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5mg/ml 20ml
Description: administered in a pericapsular nerve group (PENG) block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: administered in a pericapsular nerve group (PENG) block
Study: NCT05716100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT05623007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
Study: NCT04669457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-nasal Dexmedetomidine
Description: Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Midazolam
Description: Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
Study: NCT04775316

Intervention type: DEVICE
Intervention: Leukomed T / Tplus skin sensitive treatment
Description: Application of sterile wound dressing.
Study: NCT05343273

Intervention type: DIAGNOSTIC_TEST
Intervention: taking a blood sample
Description: blood collection for routine biochemical analysis
Study: NCT05718544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 50 mg is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Study: NCT04732156

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Measurement of PHI Index

Intervention type: OTHER
Group type: OTHER
Intervention: Follow up questionnaire
Description: 3 years after inclusion

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Human reading of prostate MR images (PI-RADSv2.1).
Description: The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
Study: NCT05295797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Program
Description: Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
Study: NCT05597605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The SHINE SYSTEM
Description: The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
Study: NCT06496100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triticum Aestivum
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (calcined magnesia)
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Study: NCT05978232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAVAH
Description: Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
Study: NCT06136299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
Study: NCT05581875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin-Blmf
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered per os.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously or per os.
Study: NCT05641675

Intervention type: DIAGNOSTIC_TEST
Intervention: right heart catheterization
Description: Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
Study: NCT04235803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Description: A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
Study: NCT05927324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAVEAT
Description: Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
Study: NCT06508749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight
Study: NCT06057038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous
Study: NCT06508749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Regimen prior to enrolling in Step 1a
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Regimen prior to enrolling in Step 1a
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Regimen prior to enrolling in Step 1b
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: (all anti-HIV agents are discontinued)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: (all anti-HIV agents are discontinued)
Study: NCT05623007

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling on healthy eating, physical activity, and psychosocial stimulation
Description: Counselling on healthy eating, physical activity, and psychosocial stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on healthy eating, physical activity, and psychosocial stimulation
Description: Counselling on healthy eating, physical activity, and psychosocial stimulation.
Study: NCT04713982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Description: Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
Study: NCT06529133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural control
Description: Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural control
Description: Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
Study: NCT06332092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FID007
Description: Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FID007
Description: Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Study: NCT05494632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment-modifications to CI speech processor program
Description: We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
Study: NCT06461442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
Study: NCT04914546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05828290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Yoga
Description: The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
Study: NCT05407064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Study: NCT06057038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous
Study: NCT05407064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that is designed to have no therapeutic value.
Study: NCT05623007

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotics
Description: Maltodextrin
Study: NCT06001268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
Study: NCT06057038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenous
Study: NCT05958875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antipsychotics (treatment as usual)
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
Study: NCT06289049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12.
Study: NCT02903212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous apoptotic cells injection
Description: cells injection
Study: NCT05031598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term fasting according to the Buchinger Wilhelmi fasting program
Description: the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
Study: NCT04777838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram 10 MG
Description: 10 mg of citalopram every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25mg of Amitriptyline every
Study: NCT05806216

Intervention type: DEVICE
Intervention: EarliPoint Diagnosis
Description: Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder

Intervention type: DEVICE
Intervention: EarliPoint Diagnosis
Description: Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder

Intervention type: BEHAVIORAL
Intervention: Clinically Certain Expert Clinician Diagnosis (CC-ECD)
Description: Diagnosis by an expert clinician using gold standard developmental assessment tools.

Intervention type: BEHAVIORAL
Intervention: Clinically Certain Expert Clinician Diagnosis (CC-ECD)
Description: Diagnosis by an expert clinician using gold standard developmental assessment tools.